PRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune... These binding interactions enable the compound to modulate the function of these cells and restore the balance of the immune system.
- Mechanism
- Curator reviewed
PRTX-100 aims to restore normal immune system function by selectively modulating only the B-cells that are producing pathogenic auto-antibodies, which play a role in the induction and maintenance of autoimmune diseases. PRTX-100 achieves this specificity due to its ability to bind to immunoglobulins that are of a specific lineage, namely VH3, which is also the lineage that is most prevalent in the auto-antibodies that are present in numerous autoimmune diseases.
- Primary indication
- Investigated for use/treatment in autoimmune diseases, inflammatory disorders (unspecified), rheumatoid arthritis, and thrombocytopenia.Curator reviewed
- Code names
- PRTX-100
What you can answer from here — as of July 03, 2026
Which companies are running trials of PRTX-100, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account